Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies

NCT00208923

Hematologic Malignancies

COMPLETED PHASE2

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00448201

Chronic Myeloproliferative Disorders Leukemia Lymphoma +2 more

COMPLETED PHASE2

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

NCT01572662

Leukemia Acute Myeloid Leukemia Acute Lymphocytic Leukemia +7 more

COMPLETED PHASE2

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

NCT00448357

Chronic Myeloproliferative Disorders Leukemia Lymphoma +2 more

COMPLETED PHASE1/PHASE2

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

NCT00806767

Chronic Myeloproliferative Disorders Leukemia Lymphoma +3 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A person who has cancer of the blood or lymph glands can be treated by bone marrow transplantation (BMT). BMT has developed over several decades of research on both animal and human subjects as an effective treatment of various malignant and nonmalignant hematologic diseases. Many hematologic malignancies can be successfully treated with a combination of high-dose chemotherapy or chemo-radiotherapy and transplantation of allogeneic bone marrow or peripheral blood stem cells (alloBMT)

However, a possible side effect of BMT is graft versus host disease (GVHD). GVHD occurs when cells of the donor's immune system, which are present in the bone marrow, attack the BMT recipient's normal tissue. Prevention of GVHD is important for the success of the bone marrow transplant. This research is being done to find the most effective and least toxic way to prevent GVHD after BMT

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma Multiple Myeloma Leukemia Myelodysplastic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Busulfan, Fludarabine, Cytoxan

Busulfan once a day for 4 days

Fludarabine once a day for 4 days

Bone marrow transplant

Cytoxan two doses

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BMT Cyclophosphamide Allogeneic Transplantation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ages between 0 to and 65 years of age.
* Patient must have a genotypically HLA-identical sibling, a phenotypically matched first-degree relative or an unrelated matched donor.
* Acute lymphocytic leukemia (ALL) in CR1 with high risk features
* Acute myeloid leukemia (AML) in CR1 with high risk features defined as:

i. Greater than 1 cycle of induction therapy required to achieve remission, ii. Preceding myelodysplastic syndrome (MDS) other than myelofibrosis, secondary AML iii. Presence of Flt3 mutations or internal tandem duplications, iv. FAB M6 or M7 classification or adverse cytogenetics for overall survival such as those associated with MDS, M6, M7 leukemia, or v. Complex karyotype \[\> 3 abnormalities\]
* Acute Leukemias in 2nd or greater remission
* Refractory or Relapsed AML
* AML transformed from MDS
* Myelodysplastic syndrome (MDS) beyond refractory anemia
* Chronic myeloid leukemia (CML)
* Chronic myelomonocytic leukemia
* Philadelphia-negative myeloproliferative disorder
* Relapsed chemotherapy-sensitive Hodgkin's or Non-Hodgkin's lymphoma
* Multiple Myeloma-Stage III

Exclusion Criteria

* Prior autologous or allogeneic stem cell transplant.
* Performance status greater than 2
* Active infection.
* Inadequate cardiac function; arrythmias or symptomatic cardiac disease.
* Inadequate pulmonary function; FEV1, FVC, DLCO \<50% of predicted
* Inadequate Serum creatinine clearance \<60
* InadequatebHepatic function
* Positive serology for HIV-1, 2 or HTLV-1, 2.
* Pregnancy. Female patient must have negative pregnancy test

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No